Tamsulosin shows a higher unbound drug fraction in human prostate than in plasma: a basis for uroselectivity?
Authors:
- 11 July 2011
- journal article
- research article
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 72 (2) , 218-225
Abstract
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT• The efficacy‐tolerability profile of tamsulosin in patients with benign prostatic hyperplasia (BPH) is assumed to be associated both with the α1‐adrenoceptor selectivity profile of the drug and a small peak : trough ratio in the plasma pharmacokinetic (PK) profile. Tamsulosin is highly bound to plasma proteins, notably α1‐acid glycoprotein (AGP). This protein is a high‐affinity binding protein and AGP plasma concentration was found to influence the therapeutic (unbound) plasma concentrations for high‐AGP‐binding drugs.WHAT THIS STUDY ADDS• The study actually assessed unbound tamsulosin concentrations in both blood plasma and prostate tissue and reported that the unbound tamsulosin concentrations after multiple dosing in men with BPH, were much higher in prostate than in blood plasma. The assumption is put forward that differential free drug concentrations in prostate and blood plasma may contribute to the relative ‘uroselectivity’ of tamsulosin.AIMThe aim of this small patient study was to investigate tamsulosin concentrations in prostate and plasma samples in order to identify potential differences in the pharmacokinetics (PK) in plasma and prostate contributing to its pharmacodynamic activity profile in patients.METHODSForty‐one patients with benign prostatic hyperplasia (BPH) scheduled for open prostatectomy were given tamsulosin 0.4 mg for 6–21 days in order to reach steady‐state PK. Patients were randomized over four groups to allow collection of plasma and tissue samples at different time points after last dose administration. Samples were collected during surgery and assayed for tamsulosin HCl. The free fraction (fu) of tamsulosin was determined by ultracentrifugation of plasma and prostate tissue spiked with14C‐tamsulosin.RESULTSCmaxin plasma at 4.4 h for total tamsulosin was 15.2 ng ml−1and AUC(0,24 h) was 282 ng ml−1 h, while for prostateCmaxat 11.4 h post‐dose was 5.4 ng ml−1and AUC(0,24 h) was 120 ng ml−1 h. AUC(0,24 h) for total tamsulosin in prostate was 43% of the plasma AUC(0,24 h).fuwas 0.4 % for plasma and 59.1% for prostate. Therefore calculated on unbound tamsulosin, a ratio of 63 resulted for prostatevs.plasmaCmaxconcentrations.CONCLUSIONSThese data indicate that in patients with confirmed BPH the amount of tamsulosin freely available in the target tissue (prostate) is much higher than in plasma.Keywords
This publication has 35 references indexed in Scilit:
- α1‐Adrenoceptor subtypes and lower urinary tract symptomsInternational Journal of Urology, 2008
- A Shifted Paradigm for the Further Understanding, Evaluation, and Treatment of Lower Urinary Tract Symptoms in Men: Focus on the BladderEuropean Urology, 2006
- Modeling of Relationships between Pharmacokinetics and Blockade of Agonist-Induced Elevation of Intraurethral Pressure and Mean Arterial Pressure in Conscious Dogs Treated with α1-Adrenoceptor AntagonistsThe Journal of Pharmacology and Experimental Therapeutics, 2002
- HUMAN ALPHA-1-GLYCOPROTEIN AND ITS INTERACTIONS WITH DRUGS†,‡Drug Metabolism Reviews, 2001
- Differential vascular α1‐adrenoceptor antagonism by tamsulosin and terazosinBritish Journal of Clinical Pharmacology, 1999
- α1-Blockers for BPH: Are There Differences?European Urology, 1999
- TAMSULOSIN TREATMENT OF 19,365 PATIENTS WITH LOWER URINARY TRACT SYMPTOMSJournal of Urology, 1998
- Functional UroselectivityEuropean Urology, 1998
- The effects of tamsulosin, a high affinity antagonist at functional α1A‐ and α1D‐adrenoceptor subtypesBritish Journal of Pharmacology, 1997
- Use of recombinant α1-adrenoceptors to characterize subtype selectivity of drugs for the treatment of prostatic hypertrophyEuropean Journal of Pharmacology: Molecular Pharmacology, 1995